Tilikum – Cancer Therapeutics
Categories: Health Care
Tilikum is a biotechnology company developing a new class of small-molecule cancer therapies aimed at solid tumors that no longer respond to approved drugs. Spun out of Oregon Health & Science University, the company is building a third-generation PARP1 inhibitor that targets the underlying biology of treatment resistance rather than working around it. The science is unusually distinctive — a novel “PARP-locking” mechanism that does not depend on pre-existing DNA-repair defects — and the website needed to communicate that with the clarity expected by a scientific and investor audience. FusionWorks designed and built Tilikum’s corporate website to match the seriousness and ambition of the underlying research.
A New Mechanism for Treatment-Resistant Tumors
Tilikum’s lead compounds act through a different mechanism than conventional PARP inhibitors. Where existing drugs rely on synthetic lethality in tumors with pre-existing DNA-repair defects, Tilikum’s PARP-locking compounds arrest DNA replication and repair across a broader population of tumors, including those without genetic defects in DNA-repair machinery. Additionally, preliminary data on the lead candidate Pip6 has indicated dramatic improvements in toxicity to cancer cells compared to predecessor compounds. This positions Tilikum’s platform as a credible answer to one of oncology’s hardest problems: tumors that have stopped responding to approved drugs.
Expanding the Patient Population
Commercially approved PARP1 inhibitors are currently used in a small set of patients with defined subtypes of ovarian, breast, prostate, and pancreatic cancers marked by specific genetic defects. Tilikum’s compounds are designed to be active in patients with the same diseases who are not eligible for current PARP1 inhibitors — either because they lack the genetic defect or because they have developed drug resistance. Furthermore, the company is exploring both orally administered and ADC-delivered formulations, broadening the clinical settings where the drugs could be deployed. This significantly expands the addressable population for an already validated drug class.
A Communication Platform for a Scientific Audience
The Tilikum website needed to do real work — explaining a complex mechanism to a sophisticated audience of clinicians, scientists, partners, and investors without dumbing down the science. The site was built to present the company’s platform, pipeline, team, and publications in a clean, navigable structure that respects the reader. Meanwhile, the visual identity carries the sense of precision and seriousness appropriate for a clinical-stage biotech. This is the kind of communication infrastructure a company actually depends on during the years between discovery and clinical readout.
Development and Implementation
FusionWorks built the Tilikum website on WordPress, chosen for the editorial flexibility a growing biotech needs as its publications, news, and pipeline updates evolve. Our team designed and implemented the site’s structure, page templates, and content management workflow so Tilikum’s small team can keep it current without engineering support. We handled the visual design, the performance and accessibility work, and the SEO basics required for a company website to be findable by the audiences that matter. Furthermore, the site is set up to scale as Tilikum’s pipeline and publications grow.
Tilikum’s orally administered and ADC-delivered small molecules have the potential to transform cancer care for treatment-resistant disease, and the website now serves as a clear, credible front door for that work.
Tech: WordPress
